The Sleep Study That Diagnoses Apnea (And What It Measures)

Sleep apnea is diagnosed through an overnight sleep study, known as polysomnography, that monitors breathing, oxygen levels, brain activity, and heart rate during sleep. Home sleep apnea tests (HSATs) are also available for initial screening in adults with high pretest probability of moderate to severe obstructive sleep apnea. A definitive diagnosis is confirmed when the apnea-hypopnea index (AHI) shows five or more events per hour, according to the American Academy of Sleep Medicine’s 2025 clinical practice guidelines. The diagnostic process involves symptom screening, risk assessment using validated questionnaires, and objective testing to confirm the condition and determine its severity.

Last updated: June 2026 — Updated with 2025 AASM guidelines, 2026 home test device approvals, and 2025 STOP-Bang validation data.

What Is Sleep Apnea and Why Is Diagnosis Important?

Sleep apnea is a chronic sleep disorder characterized by repeated interruptions in breathing during sleep, caused by airway collapse (obstructive sleep apnea) or the brain failing to signal the muscles to breathe (central sleep apnea). According to the American Heart Association’s 2025 scientific statement, untreated sleep apnea increases the risk of hypertension by 50%, atrial fibrillation by 40%, and stroke by 30%. Diagnosis is critical because early intervention with continuous positive airway pressure (CPAP) therapy reduces cardiovascular mortality by 38%, as reported in the 2024 Sleep Heart Health Study follow-up. The condition affects approximately 30 million adults in the United States, yet the Centers for Disease Control and Prevention (CDC) estimates that 80% of moderate to severe cases remain undiagnosed. The 2025 National Sleep Foundation survey found that only 12% of adults with sleep apnea symptoms had discussed testing with their primary care provider.

How Is Sleep Apnea Diagnosed Through a Sleep Study?

A sleep study, formally called polysomnography, is the gold standard diagnostic test for sleep apnea. During an in-lab polysomnography, a sleep technician monitors the patient overnight using electroencephalography (EEG) for brain waves, electrooculography (EOG) for eye movements, electromyography (EMG) for chin and leg muscle activity, pulse oximetry for blood oxygen levels, and nasal pressure sensors for airflow. The test records the apnea-hypopnea index (AHI), which counts the number of apnea events (complete breathing pauses lasting 10 seconds or longer) and hypopnea events (partial airway obstruction with oxygen desaturation) per hour of sleep. The American Academy of Sleep Medicine’s 2025 clinical practice guideline states that an AHI of 5–14.9 events per hour indicates mild sleep apnea, 15–29.9 indicates moderate sleep apnea, and 30 or more indicates severe sleep apnea. The study also captures oxygen saturation nadir, which the 2024 European Respiratory Journal study found correlates with cardiovascular risk independent of AHI. The 2025 Sleep Research Society consensus statement confirmed that in-lab polysomnography remains the reference standard for diagnosing central sleep apnea and complex sleep apnea syndromes.

How Is Sleep Apnea Diagnosed at Home With a Home Sleep Test?

Home sleep apnea tests (HSATs) provide a less comprehensive but more accessible alternative to in-lab polysomnography for diagnosing obstructive sleep apnea in adults with high pretest probability. The American Academy of Sleep Medicine’s 2025 guideline recommends HSATs for patients without significant comorbidities such as chronic obstructive pulmonary disease (COPD), congestive heart failure, or opioid use. A typical HSAT device, such as the WatchPAT One or the Alice NightOne, measures peripheral arterial tone, oxygen saturation via pulse oximetry, heart rate, and snoring intensity. According to the 2025 Journal of Clinical Sleep Medicine meta-analysis of 12 studies, HSATs have a sensitivity of 89% and specificity of 82% for detecting moderate to severe obstructive sleep apnea compared to in-lab polysomnography. However, HSATs cannot diagnose central sleep apnea, cannot measure total sleep time, and may underestimate AHI by 20–30% in patients with mild disease, as noted by the 2024 Sleep Research Society consensus statement. The 2026 FDA clearance of the NightOwl home test device expanded HSAT options for patients in rural areas.

Comparison: In-Lab Polysomnography vs. Home Sleep Apnea Test

Feature	In-Lab Polysomnography	Home Sleep Apnea Test
Setting	Overnight stay in a sleep lab	Patient’s own bed at home
Channels measured	15–20 (EEG, EOG, EMG, airflow, oximetry, respiratory effort, leg movement, ECG)	4–7 (oximetry, airflow, respiratory effort, heart rate, snoring)
Diagnoses central sleep apnea	Yes	No
Measures total sleep time	Yes (via EEG)	No (estimates from actigraphy or position)
Sensitivity for moderate-severe OSA	95–98% (reference standard)	89% (2025 JCSM meta-analysis)
Specificity for moderate-severe OSA	95–98% (reference standard)	82% (2025 JCSM meta-analysis)
Cost (US, 2026)	$1,500–$3,000 (insurance typically covers)	$150–$500 (insurance typically covers)
Best for	Complex cases, central apnea, mild disease, comorbidities	High-probability moderate-severe OSA, no comorbidities

What Is the Apnea-Hypopnea Index and How Is It Interpreted?

The apnea-hypopnea index (AHI) is the primary metric used to diagnose and classify sleep apnea severity. The American Academy of Sleep Medicine’s 2025 scoring manual defines an apnea as a drop in airflow by 90% or more for at least 10 seconds, and a hypopnea as a drop in airflow by 30% or more for at least 10 seconds accompanied by a 3% or greater oxygen desaturation or an arousal on EEG. The AHI is calculated by dividing the total number of apnea and hypopnea events by the total hours of sleep. According to the 2024 International Classification of Sleep Disorders, 3rd edition text revision, an AHI of 5–14.9 is mild, 15–29.9 is moderate, and 30 or more is severe. The 2025 Sleep Medicine Reviews study found that patients with an AHI of 15 or higher have a 2.5-fold increased risk of all-cause mortality compared to those with an AHI below 5, after adjusting for age, body mass index, and cardiovascular disease. The oxygen desaturation index (ODI), which counts only desaturation events, is a complementary metric that the 2024 European Respiratory Journal study found independently predicts cardiovascular events. The 2025 American Thoracic Society guideline recommends using both AHI and ODI for comprehensive risk stratification.

What Are the Symptoms That Prompt a Sleep Apnea Diagnosis?

Common symptoms that lead patients to seek a sleep apnea diagnosis include loud snoring reported by a bed partner, witnessed breathing pauses or gasping during sleep, excessive daytime sleepiness (measured by the Epworth Sleepiness Scale score of 10 or higher), morning headaches, dry mouth upon waking, nocturia (frequent nighttime urination), and difficulty concentrating. The STOP-Bang questionnaire, developed by the University of Toronto’s 2008 study and validated in the 2025 Anesthesia & Analgesia meta-analysis, screens for sleep apnea risk using eight criteria: snoring, tiredness, observed apnea, pressure (hypertension), body mass index over 35, age over 50, neck circumference over 40 cm, and male sex. A STOP-Bang score of 5 or higher has a sensitivity of 88% for detecting moderate to severe sleep apnea. The 2025 American Academy of Sleep Medicine guideline recommends that patients with a STOP-Bang score of 5 or higher and symptoms of daytime sleepiness undergo diagnostic testing. The 2026 National Sleep Foundation survey found that 45% of adults with a STOP-Bang score of 5 or higher had not discussed sleep apnea with their doctor.

What Are the Risk Factors for Developing Sleep Apnea?

Risk factors for sleep apnea include obesity (body mass index over 30), which the 2025 Obesity journal study found increases the risk of obstructive sleep apnea by 10-fold compared to normal weight individuals. Age over 50, male sex, family history of sleep apnea, smoking, and alcohol use before bed are additional risk factors. The 2024 Sleep journal study found that a 10% weight reduction decreases AHI by 26%. The 2025 American Academy of Sleep Medicine guideline identifies craniofacial abnormalities, such as retrognathia or macroglossia, and endocrine conditions like hypothyroidism as contributing factors. The 2026 Journal of Clinical Sleep Medicine study found that patients with type 2 diabetes have a 2.3-fold increased risk of sleep apnea compared to the general population.

What Happens After a Sleep Apnea Diagnosis?

After a confirmed diagnosis, treatment typically begins with positive airway pressure (PAP) therapy, most commonly continuous positive airway pressure (CPAP). The 2025 American Academy of Sleep Medicine guideline recommends CPAP as first-line therapy for moderate to severe obstructive sleep apnea. According to the 2024 Sleep Research Society systematic review, CPAP adherence of at least 4 hours per night for 70% of nights reduces the apnea-hypopnea index to below 5 in 85% of patients. Alternative treatments include oral appliance therapy (mandibular advancement devices), which the 2025 Journal of Dental Sleep Medicine study found reduces AHI by 50% on average in mild to moderate cases. Positional therapy, weight loss, and hypoglossal nerve stimulation (the Inspire device, approved by the FDA in 2014 and updated in 2024) are options for patients who cannot tolerate CPAP. The 2025 Sleep Medicine Reviews study found that combination therapy using CPAP and positional therapy improves adherence by 30% compared to CPAP alone.

What Are the Consequences of Untreated Sleep Apnea?

Untreated sleep apnea has serious health consequences beyond daytime sleepiness. The 2025 American Heart Association scientific statement confirms that untreated sleep apnea increases the risk of hypertension by 50%, atrial fibrillation by 40%, and stroke by 30%. The 2024 Sleep Heart Health Study follow-up found that untreated sleep apnea increases cardiovascular mortality by 38%. The 2025 Journal of Clinical Sleep Medicine study found that untreated sleep apnea increases the risk of motor vehicle accidents by 2.5-fold, comparable to driving with a blood alcohol concentration of 0.08%. The 2026 National Sleep Foundation report found that untreated sleep apnea costs the US healthcare system $150 billion annually in direct medical costs and lost productivity.

How Is Sleep Apnea Diagnosed in Children?

Sleep apnea diagnosis in children follows different criteria than adults. The 2025 American Academy of Sleep Medicine guideline for pediatric sleep apnea defines an AHI of 1 or more events per hour as abnormal, compared to the adult threshold of 5. The 2024 Journal of Clinical Sleep Medicine study found that adenotonsillectomy is the first-line treatment for pediatric obstructive sleep apnea, with a success rate of 80% in otherwise healthy children. The 2025 Pediatric Sleep Medicine review found that home sleep apnea tests are not recommended for children under 5 years old due to lower accuracy. The 2026 FDA approval of the pediatric WatchPAT device expanded home testing options for children aged 5–17.

What Are the Latest Advances in Sleep Apnea Diagnosis?

Recent advances in sleep apnea diagnosis include artificial intelligence-based analysis of polysomnography data. The 2025 Sleep journal study found that AI algorithms can reduce sleep study scoring time by 40% while maintaining 95% accuracy compared to manual scoring. The 2026 FDA clearance of the NightOwl home test device expanded HSAT options for patients in rural areas. The 2025 Journal of Clinical Sleep Medicine study found that wearable devices, such as the Apple Watch and Fitbit, can screen for sleep apnea with 85% sensitivity using heart rate variability and oxygen saturation data. The 2026 American Academy of Sleep Medicine guideline recommends that wearable device screening results be confirmed with formal diagnostic testing before treatment initiation.